PL3377064T3 - Orwepitant do leczenia przewlekłego kaszlu - Google Patents

Orwepitant do leczenia przewlekłego kaszlu

Info

Publication number
PL3377064T3
PL3377064T3 PL16819325T PL16819325T PL3377064T3 PL 3377064 T3 PL3377064 T3 PL 3377064T3 PL 16819325 T PL16819325 T PL 16819325T PL 16819325 T PL16819325 T PL 16819325T PL 3377064 T3 PL3377064 T3 PL 3377064T3
Authority
PL
Poland
Prior art keywords
orvepitant
treatment
chronic cough
cough
chronic
Prior art date
Application number
PL16819325T
Other languages
English (en)
Inventor
Mike TROWER
Original Assignee
Nerre Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Limited filed Critical Nerre Therapeutics Limited
Publication of PL3377064T3 publication Critical patent/PL3377064T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16819325T 2016-01-08 2016-12-27 Orwepitant do leczenia przewlekłego kaszlu PL3377064T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662276237P 2016-01-08 2016-01-08
US201662408921P 2016-10-17 2016-10-17
EP16819325.8A EP3377064B1 (en) 2016-01-08 2016-12-27 Orvepitant for the treatment of chronic cough
PCT/EP2016/082698 WO2017118584A1 (en) 2016-01-08 2016-12-27 Orvepitant for the treatment of chronic cough

Publications (1)

Publication Number Publication Date
PL3377064T3 true PL3377064T3 (pl) 2020-02-28

Family

ID=57629591

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819325T PL3377064T3 (pl) 2016-01-08 2016-12-27 Orwepitant do leczenia przewlekłego kaszlu

Country Status (22)

Country Link
US (2) US9750739B2 (pl)
EP (1) EP3377064B1 (pl)
JP (1) JP6621534B2 (pl)
KR (1) KR102136017B1 (pl)
CN (2) CN108430475B (pl)
AU (1) AU2016384267B2 (pl)
BR (1) BR112018013903B1 (pl)
CA (1) CA3009283C (pl)
CY (1) CY1122170T1 (pl)
DK (1) DK3377064T3 (pl)
ES (1) ES2738678T3 (pl)
HR (1) HRP20191725T1 (pl)
HU (1) HUE045764T2 (pl)
LT (1) LT3377064T (pl)
MX (2) MX393779B (pl)
PL (1) PL3377064T3 (pl)
PT (1) PT3377064T (pl)
RS (1) RS59313B1 (pl)
RU (1) RU2746601C2 (pl)
SI (1) SI3377064T1 (pl)
SM (1) SMT201900510T1 (pl)
WO (1) WO2017118584A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180235931A1 (en) * 2017-01-17 2018-08-23 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives
CN118512451A (zh) * 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
CN112823795B (zh) * 2019-11-20 2023-04-14 天津医科大学总医院 一种特发性肺纤维化药物组合及其应用
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
BR112022018876A2 (pt) * 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
CN114732818B (zh) * 2022-04-29 2023-02-10 首都医科大学附属北京胸科医院 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
WO2014057003A1 (en) * 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses

Also Published As

Publication number Publication date
RS59313B1 (sr) 2019-10-31
RU2018122121A (ru) 2020-02-11
SI3377064T1 (sl) 2019-11-29
US20170196860A1 (en) 2017-07-13
KR20180100651A (ko) 2018-09-11
CY1122170T1 (el) 2020-11-25
CA3009283A1 (en) 2017-07-13
AU2016384267B2 (en) 2022-02-03
SMT201900510T1 (it) 2019-11-13
CA3009283C (en) 2023-10-03
EP3377064A1 (en) 2018-09-26
KR102136017B1 (ko) 2020-07-20
CN108430475B (zh) 2021-03-16
US20170326140A1 (en) 2017-11-16
AU2016384267A1 (en) 2018-07-05
LT3377064T (lt) 2019-09-10
MX371178B (es) 2020-01-21
BR112018013903A2 (pt) 2018-12-18
HUE045764T2 (hu) 2020-01-28
BR112018013903B1 (pt) 2023-11-07
JP6621534B2 (ja) 2019-12-18
EP3377064B1 (en) 2019-06-26
ES2738678T3 (es) 2020-01-24
HRP20191725T1 (hr) 2019-12-27
JP2019501162A (ja) 2019-01-17
CN108430475A (zh) 2018-08-21
WO2017118584A1 (en) 2017-07-13
MX2018008439A (es) 2018-08-14
US9750739B2 (en) 2017-09-05
PT3377064T (pt) 2019-07-23
DK3377064T3 (da) 2019-09-23
RU2746601C2 (ru) 2021-04-16
CN113274392A (zh) 2021-08-20
MX393779B (es) 2025-03-21
RU2018122121A3 (pl) 2020-06-26

Similar Documents

Publication Publication Date Title
IL321844A (en) Menin–MLL interaction inhibitors
IL279627A (en) A method for treating depression
PL3512850T3 (pl) Inhibitory interakcji menina-mll
PL3286311T3 (pl) Sposób leczenia nowotworów złośliwych
PL3122358T3 (pl) Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
IL259996A (en) Combinations for cancer treatment
SI3261726T1 (sl) Sestavek za zdravljenje aken
GB201608885D0 (en) Treatment
PT3377064T (pt) Orvepitante para o tratamento da tosse crónica
GB201609597D0 (en) Therapy
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
PT3122349T (pt) Composições para o tratamento da autodigestão
IL270819A (en) Methods for the treatment of chronic pouchitis
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL265474A (en) leading catheter
GB201402179D0 (en) Surface treatment
GB201618477D0 (en) Therapy
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201615923D0 (en) Macrophage-based therapy
GB201609721D0 (en) Cobination therapy
GB201609312D0 (en) Therapy
GB201609322D0 (en) Therapy